Effect of altered dietary n-3 fatty acid intake upon plasma lipid fatty acid composition, conversion of [13C]alpha-linolenic acid to longer-chain fatty acids and partitioning towards beta-oxidation in older men

Br J Nutr. 2003 Aug;90(2):311-21. doi: 10.1079/bjn2003901.

Abstract

The effect of increased dietary intakes of alpha-linolenic acid (ALNA) or eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for 2 months upon plasma lipid composition and capacity for conversion of ALNA to longer-chain metabolites was investigated in healthy men (52 (SD 12) years). After a 4-week baseline period when the subjects substituted a control spread, a test meal containing [U-(13)C]ALNA (700 mg) was consumed to measure conversion to EPA, docosapentaenoic acid (DPA) and DHA over 48 h. Subjects were then randomised to one of three groups for 8 weeks before repeating the tracer study: (1) continued on same intake (control, n 5); (2) increased ALNA intake (10 g/d, n 4); (3) increased EPA+DHA intake (1.5 g/d, n 5). At baseline, apparent fractional conversion of labelled ALNA was: EPA 2.80, DPA 1.20 and DHA 0.04 %. After 8 weeks on the control diet, plasma lipid composition and [(13)C]ALNA conversion remained unchanged compared with baseline. The high-ALNA diet resulted in raised plasma triacylglycerol-EPA and -DPA concentrations and phosphatidylcholine-EPA concentration, whilst [(13)C]ALNA conversion was similar to baseline. The high-(EPA+DHA) diet raised plasma phosphatidylcholine-EPA and -DHA concentrations, decreased [(13)C]ALNA conversion to EPA (2-fold) and DPA (4-fold), whilst [(13)C]ALNA conversion to DHA was unchanged. The dietary interventions did not alter partitioning of ALNA towards beta-oxidation. The present results indicate ALNA conversion was down-regulated by increased product (EPA+DHA) availability, but was not up-regulated by increased substrate (ALNA) consumption. This suggests regulation of ALNA conversion may limit the influence of variations in dietary n-3 fatty acid intake on plasma lipid compositions.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carbon Dioxide / metabolism
  • Dietary Fats, Unsaturated / administration & dosage
  • Dietary Fats, Unsaturated / metabolism
  • Docosahexaenoic Acids / administration & dosage
  • Docosahexaenoic Acids / metabolism
  • Eicosapentaenoic Acid / administration & dosage
  • Eicosapentaenoic Acid / metabolism
  • Fatty Acids / blood
  • Fatty Acids, Unsaturated / administration & dosage
  • Humans
  • Lipids / blood
  • Male
  • Middle Aged
  • Oxidation-Reduction
  • alpha-Linolenic Acid / administration & dosage*
  • alpha-Linolenic Acid / metabolism*

Substances

  • Dietary Fats, Unsaturated
  • Fatty Acids
  • Fatty Acids, Unsaturated
  • Lipids
  • alpha-Linolenic Acid
  • Carbon Dioxide
  • Docosahexaenoic Acids
  • Eicosapentaenoic Acid
  • docosapentaenoic acid